ST. GEORGE — Intermountain Healthcare and Prisma Biotech have announced a collaboration to allow Prisma Biotech to distribute a test in Taiwan that facilitates personalized medicine.
Prisma Biotech, an in vitro diagnostic supplier company based in Taiwan, now contracts with Intermountain Precision Genomics to offer ICG100 testing through its wholly owned subsidiary ReadGene Inc.
Intermountain Precision Genomics ICG100 test is next-generation sequencing that identifies mutations within a person’s cancer to identify specific DNA targets for personalized drug treatments.
Currently approved for late-stage cancer patients who have failed a traditional treatment method, the ICG100 test offers new hope where traditional treatments fall short.
“Intermountain Healthcare has been one of the early adaptors of precision cancer genomics. We are very excited to be a partner of Intermountain Precision Genomics to introduce the comprehensive, end-to-end service to Taiwan, including testing, the molecular tumor board, matching drugs, and monitoring the outcome. This will assist oncologists in Taiwan to implement precision genomics in treatment of cancer patients,” Prisma President and CEO Kevin Hung-Pin Tseng said.
This new collaboration follows a similar agreement between Intermountain Precision Genomics and Asia Genomics.
“We are pleased to partner with Prisma Biotech to help extend life and improve quality of life for late-stage cancer patients across East Asia,” Jason Gillman, director of Intermountain Precision Genomics, said. “Targeted therapies are the most effective treatment for late-stage cancer patients and we look forward to this partnership positively impacting the way patients receive care around the world.”
Intermountain Precision Genomics is a service of Intermountain Healthcare, which offers genetic sequencing of solid tumors. This in-depth sequencing identifies individual mutations within a person’s cancer cells to identify specific DNA targets for personalized drugs.
Read more: Genomics lab … facilitates targeted therapies for cancer patients (video included)
Prisma Biotech serves a broad range of customers including in vitro diagnostic developers and manufacturers, hospitals, central labs and genomic testing labs. Prisma Biotech has been in the diagnostic industry for more than 20 years.